267 related articles for article (PubMed ID: 25205489)
1. Muscle wasting: an overview of recent developments in basic research.
Palus S; von Haehling S; Springer J
Int J Cardiol; 2014 Oct; 176(3):640-4. PubMed ID: 25205489
[TBL] [Abstract][Full Text] [Related]
2. Muscle wasting: an overview of recent developments in basic research.
Palus S; von Haehling S; Springer J
J Cachexia Sarcopenia Muscle; 2014 Sep; 5(3):193-8. PubMed ID: 25163459
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency?
Fontes-Oliveira CC; Busquets S; Toledo M; Penna F; Paz Aylwin M; Sirisi S; Silva AP; Orpí M; García A; Sette A; Inês Genovese M; Olivan M; López-Soriano FJ; Argilés JM
Biochim Biophys Acta; 2013 Mar; 1830(3):2770-8. PubMed ID: 23200745
[TBL] [Abstract][Full Text] [Related]
4. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.
Song YH; Li Y; Du J; Mitch WE; Rosenthal N; Delafontaine P
J Clin Invest; 2005 Feb; 115(2):451-8. PubMed ID: 15650772
[TBL] [Abstract][Full Text] [Related]
5. Selumetinib Attenuates Skeletal Muscle Wasting in Murine Cachexia Model through ERK Inhibition and AKT Activation.
Quan-Jun Y; Yan H; Yong-Long H; Li-Li W; Jie L; Jin-Lu H; Jin L; Peng-Guo C; Run G; Cheng G
Mol Cancer Ther; 2017 Feb; 16(2):334-343. PubMed ID: 27599525
[TBL] [Abstract][Full Text] [Related]
6. F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.
Sukari A; Muqbil I; Mohammad RM; Philip PA; Azmi AS
Semin Cancer Biol; 2016 Feb; 36():95-104. PubMed ID: 26804424
[TBL] [Abstract][Full Text] [Related]
7. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
8. Luteolin reduces cancer‑induced skeletal and cardiac muscle atrophy in a Lewis lung cancer mouse model.
Chen T; Li B; Xu Y; Meng S; Wang Y; Jiang Y
Oncol Rep; 2018 Aug; 40(2):1129-1137. PubMed ID: 29845270
[TBL] [Abstract][Full Text] [Related]
9. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice.
Winbanks CE; Murphy KT; Bernardo BC; Qian H; Liu Y; Sepulveda PV; Beyer C; Hagg A; Thomson RE; Chen JL; Walton KL; Loveland KL; McMullen JR; Rodgers BD; Harrison CA; Lynch GS; Gregorevic P
Sci Transl Med; 2016 Jul; 8(348):348ra98. PubMed ID: 27440729
[TBL] [Abstract][Full Text] [Related]
10. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy.
Glass DJ
Nat Cell Biol; 2003 Feb; 5(2):87-90. PubMed ID: 12563267
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of skeletal muscle atrophy.
Ventadour S; Attaix D
Curr Opin Rheumatol; 2006 Nov; 18(6):631-5. PubMed ID: 17053511
[TBL] [Abstract][Full Text] [Related]
12. Reduced sucrose nonfermenting AMPK-related kinase (SNARK) activity aggravates cancer-induced skeletal muscle wasting.
Alves CRR; MacDonald TL; Nigro P; Pathak P; Hirshman MF; Goodyear LJ; Lessard SJ
Biomed Pharmacother; 2019 Sep; 117():109197. PubMed ID: 31387190
[TBL] [Abstract][Full Text] [Related]
13. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
14. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
Sandri M; Sandri C; Gilbert A; Skurk C; Calabria E; Picard A; Walsh K; Schiaffino S; Lecker SH; Goldberg AL
Cell; 2004 Apr; 117(3):399-412. PubMed ID: 15109499
[TBL] [Abstract][Full Text] [Related]
15. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice.
Cai D; Frantz JD; Tawa NE; Melendez PA; Oh BC; Lidov HG; Hasselgren PO; Frontera WR; Lee J; Glass DJ; Shoelson SE
Cell; 2004 Oct; 119(2):285-98. PubMed ID: 15479644
[TBL] [Abstract][Full Text] [Related]
16. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system.
Op den Kamp CM; Langen RC; Minnaard R; Kelders MC; Snepvangers FJ; Hesselink MK; Dingemans AC; Schols AM
Lung Cancer; 2012 Apr; 76(1):112-7. PubMed ID: 22018880
[TBL] [Abstract][Full Text] [Related]
17. The role of TGF-β signaling in muscle atrophy, sarcopenia and cancer cachexia.
Lan XQ; Deng CJ; Wang QQ; Zhao LM; Jiao BW; Xiang Y
Gen Comp Endocrinol; 2024 Jul; 353():114513. PubMed ID: 38604437
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of MuRF1 and MAFbx participates to muscle wasting upon gentamicin-induced acute kidney injury.
Aniort J; Polge C; Claustre A; Combaret L; Béchet D; Attaix D; Heng AE; Taillandier D
Int J Biochem Cell Biol; 2016 Oct; 79():505-516. PubMed ID: 27102410
[TBL] [Abstract][Full Text] [Related]
19. Muscle wasting in cancer.
Johns N; Stephens NA; Fearon KC
Int J Biochem Cell Biol; 2013 Oct; 45(10):2215-29. PubMed ID: 23770121
[TBL] [Abstract][Full Text] [Related]
20. Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment.
Drescher C; Konishi M; Ebner N; Springer J
Int J Cardiol; 2016 Jan; 202():766-72. PubMed ID: 26474466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
